Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

Por van Vollenhoven, R F, Brannemark, S, Klareskog, L
Publicado em 2004

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can ma...

Por van Vollenhoven, R, Harju, A, Brannemark, S, Klareskog, L
Publicado em 2003

Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?

Por Yazici, Y, Erkan, D, van Vollenhoven, R F
Publicado em 2004

Feasibility of 1 hour infliximab infusions

Por van Vollenhoven, R F, Gullstrom, E, Klareskog, L
Publicado em 2005

Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description

Por Wick, M, Lindblad, S, Klareskog, L, van Vollenhoven, R F
Publicado em 2004

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors

Por Berg, L, Lampa, J, Rogberg, S, van Vollenhoven, R, Klareskog, L
Publicado em 2001

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled...

Por van Vollenhoven, R. F., Wax, S., Li, Y., Tak, P. P.
Publicado no Arthritis Rheumatol (2015)

Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis

Por Wick, M, Lindblad, S, Weiss, R, Klareskog, L, van Vollenhoven, R F
Publicado em 2005

CD28nullCD4(+ )T cells: an effector memory T cell population in patients with rheumatoid arthritis

Por Fasth, AER, Cao, D, van Vollenhoven, R, Trollmo, C, Malmström, V
Publicado em 2004

CD25brightCD4(+ )regulatory T cells accumulate in inflamed joints of patients with chronic rheumatic disease

Por Cao, D, van Vollenhoven, R, Klareskog, L, Trollmo, C, Malmström, V
Publicado em 2004

Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky

Por Rusman, T., van Vollenhoven, R. F., van der Horst-Bruinsma, I. E.
Publicado no Curr Rheumatol Rep (2018)

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial

Por van der Heijde, D, Landewé, R, van Vollenhoven, R, Fatenejad, S, Klareskog, L
Publicado em 2008

Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies

Por Jonsdottir, T, Forslid, J, van Vollenhoven, A, Harju, A, Brannemark, S, Klareskog, L, van Vollenhoven, R F
Publicado em 2004

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity an...

Por Ronnelid, J, Wick, M, Lampa, J, Lindblad, S, Nordmark, B, Klareskog, L, van Vollenhoven, R F
Publicado em 2005

Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists

Por Lesuis, N, den Broeder, A A, Hulscher, M E J L, van Vollenhoven, R F
Publicado no RMD Open (2016)

ACR Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From the RAPID 1 Trial

Por van Vollenhoven, R.F., Felson, D., Strand, V., Weinblatt, M.E., Luijtens, K., Keystone, E. C.
Publicado em 2011

Swedish registers to examine drug safety and clinical issues in RA

Por Askling, J, Fored, C M, Geborek, P, Jacobsson, L T H, van Vollenhoven, R, Feltelius, N, Lindblad, S, Klareskog, L
Publicado em 2006

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

Por Bykerk, V P, Cush, J, Winthrop, K, Calabrese, L, Lortholary, O, de Longueville, M, van Vollenhoven, R, Mariette, X
Publicado no Ann Rheum Dis (2015)

The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic...

Por Mariette, X, Vencovsky, J, Lortholary, O, Gomez-Reino, J, de Longueville, M, Ralston, P, Weinblatt, M, van Vollenhoven, R
Publicado no RMD Open (2015)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24...

Por Emery, P, Keystone, E, Tony, H P, Cantagrel, A, van Vollenhoven, R, Sanchez, A, Alecock, E, Lee, J, Kremer, J
Publicado em 2008